Show simple item record

dc.contributor.authorMenéndez, Javier A.
dc.contributor.authorVázquez-Martín, Alejandro
dc.contributor.authorColomer, Ramón
dc.contributor.authorBrunet, Joan
dc.contributor.authorCarrasco-Pancorbo, Alegría
dc.contributor.authorGarcía-Villalba, Rocío
dc.contributor.authorFernández Gutiérrez, Alberto 
dc.contributor.authorSegura Carretero, Antonio 
dc.date.accessioned2014-04-01T11:51:41Z
dc.date.available2014-04-01T11:51:41Z
dc.date.issued2007
dc.identifier.citationMenéndez, J.A.; et al. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells. BMC Cancer, 7: 80 (2007). [http://hdl.handle.net/10481/31177]es_ES
dc.identifier.issn1471-2407
dc.identifier.otherdoi: 10.1186/1471-2407-7-80
dc.identifier.urihttp://hdl.handle.net/10481/31177
dc.description.abstract[Background] A low incidence of breast cancer in the Mediterranean basin suggests that a high consumption of Extra Virgin Olive Oil (EVOO) might confer this benefit. While the anti-HER2 oncogene effects of the main ω-9 fatty acid present in EVOO triacylglycerols (i.e., oleic acid) have been recently described, the anti-breast cancer activities of EVOO non-glyceridic constituents -which consist of at least 30 phenolic compounds-, remained to be evaluated. [Methods] Semi-preparative HPLC was used to isolate EVOO polyphenols (i.e., tyrosol, hydroxytyrosol, oleuropein). Both the anti-proliferative and the pro-apoptotic effects of EVOO phenolics were evaluated by using MTT-based quantification of metabolically viable cells and ELISA-based detection of histone-associated DNA fragments, respectively. The nature of the interaction between oleuropein aglycone and the anti-HER2 monoclonal antibody trastuzumab (Herceptin™) was mathematically evaluated by the dose-oriented isobologram technique. HER2-specific ELISAs were employed to quantitatively assess both the basal cleavage of the HER2 extracellular domain (ECD) and the expression level of total HER2. The activation status of HER2 was evaluated by immunoblotting procedures using a monoclonal antibody specifically recognizing the tyrosine phosphorylated (Phosphor-Tyr1248) form of HER2. [Results] Among EVOO polyphenols tested, oleuropein aglycone was the most potent EVOO phenolic in decreasing breast cancer cell viability. HER2 gene-amplified SKBR3 cells were ~5-times more sensitive to oleuropein aglycone than HER2-negative MCF-7 cells. Retroviral infection of the HER2 oncogene in MCF-7 cells resulted in a "SKBR3-assimilated" phenotype of hypersensitivity to oleuropein aglycone. An up to 50-fold increase in the efficacy of trastuzumab occurred in the presence of oleuropein aglycone. A preclinical model of acquired autoresistance to trastuzumab (SKBR3/Tzb100 cells) completely recovered trastuzumab sensitivity (> 1,000-fold sensitization) when co-cultured in the presence of oleuropein aglycone. Indeed, the nature of the interaction between oleuropein aglycone and trastuzumab was found to be strongly synergistic in Tzb-resistant SKBR3/Tzb100 cells. Mechanistically, oleuropein aglycone treatment significantly reduced HER2 ECD cleavage and subsequent HER2 auto-phosphorylation, while it dramatically enhanced Tzb-induced down-regulation of HER2 expression. [Conclusion] Olive oil's bitter principle (i.e., oleuropein aglycone) is among the first examples of how selected nutrients from an EVOO-rich "Mediterranean diet" directly regulate HER2-driven breast cancer disease.es_ES
dc.description.sponsorshipJAM is the recipient of a Basic, Clinical and Translational Research Award (BCTR0600894) from the Susan G. Komen Breast Cancer Foundation (Texas, USA). This work was also supported by the Instituto de Salud Carlos III (Ministerio de Sanidad y Consumo, Fondo de Investigación Sanitaria -FIS-, Spain, Grants CP05-00090 and PI06-0778 to JAM, and Grant RD06-0020-0028 to JAM, RC and JB).es_ES
dc.language.isoenges_ES
dc.publisherBiomed Centrales_ES
dc.subjectAntibodieses_ES
dc.subjectMonoclonales_ES
dc.subjectBreast neoplasmses_ES
dc.subjectCell linees_ES
dc.subjectDrug resistancees_ES
dc.subjectGenes es_ES
dc.subjectPlant extractses_ES
dc.subjectPlant oilses_ES
dc.subjectPyranses_ES
dc.subjectOlive oil es_ES
dc.subjectTrastuzumabes_ES
dc.subjectOleuropeines_ES
dc.titleOlive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cellses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record